The Dengue Fever drugs in development market research report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Dengue Fever. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Dengue Fever and features dormant and discontinued products.

GlobalData tracks 109 drugs in development for Dengue Fever by 89 companies/universities/institutes. The top development phase for Dengue Fever is preclinical with 55 drugs in that stage. The Dengue Fever pipeline has 80 drugs in development by companies and 29 by universities/ institutes. Some of the companies in the Dengue Fever pipeline products market are: Johnson & Johnson, University of Queensland and BioNet-Asia.

The key targets in the Dengue Fever pipeline products market include Nonstructural Protein 4B (NS4B), Nonstructural Protein 1 (NS1), and Envelope Protein.

The key mechanisms of action in the Dengue Fever pipeline product include Nonstructural Protein 4B (NS4B) Inhibitor with four drugs in Phase II. The Dengue Fever pipeline products include eight routes of administration with the top ROA being Oral and 18 key molecule types in the Dengue Fever pipeline products market including Small Molecule, and Subunit Vaccine.

Dengue Fever overview

Dengue is a mosquito-borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from the nose, gums, or under the skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes use of analgesics, fluid replacement therapy, and healthy life style.

For a complete picture of Dengue Fever’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.